



Date: 14th February, 2025

To
The Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.

Dear Sir/Madam,

Sub: Integrated Filing (Financial) for the quarter and nine-month period ended December 31, 2024.

Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P /2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter ended December 31, 2024.

In this connection, we hereby submit the following:

- a) Financial Results – **Enclosed**
- b) Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. – **Enclosed**
- c) Disclosure of outstanding default on loans and debt securities- **Not Applicable**
- d) Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – **Not Applicable**
- e) Statement on impact of audit qualifications (for audit report with modified opinion) submitted along with annual audited financial results (applicable only for Annual Filing i.e., 4th quarter) – **Not Applicable**

The meeting commenced at 03.00 P.M. and concluded at 04.45 P.M.

This is for your information and necessary records.

Thanking you,

Yours faithfully,
For Oxygenta Pharmaceutical Limited

Dolly Lakhichand Mandhan
Company Secretary & Compliance Officer
M.No.: A66040

OXYGENTA PHARMACEUTICAL LIMITED


CIN: L24110TG1990PLC012038

Statement of Unaudited Financial Results for the Quarter and Year ended 31st December,2024

(in Rs Lakhs)

S.No	Particulars	Quarter ended			Nine Months Ended		Year ended
		December 31,2024	December 31,2023	September 30,2024	December 31,2024	December 31,2023	March 31,2024
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income						
	a. Revenue from operations	3,320.61	914.99	1400.52	5983.21	2908.97	3964.21
	b. Other income	48.82	2.84	74.93	126.00	2.96	4.24
2	Total Income (a+b)	3369.43	917.83	1475.45	6109.21	2911.93	3968.45
3	Expenses						
	a) Cost of Material Consumed	3,760.65	624.90	793.67	5620.10	2601.35	3505.52
	b) Change in Inventories	(576.22)	179.82	290.39	-351.73	59.06	(152.68)
	c) Direct Manufacturing Expenses	320.95	298.05	255.56	771.73	891.01	743.85
	d) Employee benefits expense	183.28	24.30	139.50	470.96	74.68	599.37
	e) Finance costs	38.83	36.39	69.09	148.60	99.90	266.07
	f) Depreciation and amortization expense	70.60	68.85	65.99	201.53	202.25	159.39
	g) Other expenses	67.52	34.99	138.59	303.23	91.10	237.80
	h) Prior Period Expenses	-	-	-	-	-	-
	Total Expenses	3,865.61	1,267.30	1,752.79	7,164.42	4,019.35	5,359.32
4	Profit before exceptional items and tax (2-3)	(496.19)	(349.47)	(277.34)	(1,055.22)	(1,107.42)	(1,390.87)
5	Exceptional items	-	(5.14)	-	-	(21.04)	3.70
6	Profit before Tax (4-5)	(496.19)	(354.61)	(277.34)	(1,055.22)	(1,128.47)	(1,387.17)
7	Tax expense						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	(103.36)	23.03	8.05	(240.68)	21.05	(1,039.24)
	(3) Previous year Income tax adjustment						
8	Net Profit for the Period	(392.83)	(377.64)	(285.39)	(814.54)	(1149.51)	(347.93)
9	Other comprehensive income (OCI)						
	(a) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	-	-	7.11
	(ii) Tax on items that will not be reclassified to profit or loss	0.00	-	-	-	-	-
	(b) (i) Items that will be reclassified to profit or loss	0.00	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	-	-	-	-	-
	Total Other Comprehensive income	-	-	-	-	-	7.11
10	Total Comprehensive income	(392.83)	(377.64)	(285.39)	(814.54)	(1149.51)	(340.82)
	Earnings per equity share (Face value of Rs.10/- each)						
	(1) Basic	(1.07)	(1.12)	(0.81)	(2.27)	(3.64)	(1.09)
	(2) Diluted	(1.12)	(1.07)	(0.78)	(2.27)	(3.48)	(1.04)
	Paid- up equity share capital(Face Value of Rs.10/- each)	3,698.35	3,348.35	3,548.35	3,698.35	3,348.35	334.84

V Sai Sudhakar



Notes:

- 1.The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules,2016.
 - 2.The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 14th February , 2025
 - 3.The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
 4. Total Revenue for the current quarter reported Rs 3369.43 Lakhs compared to Rs. 917.83 lakhs for the corresponding quarter of the previous year.
 5. The Loss before tax for the current quarter is Rs.496.19 Lakhs compared to Loss Before tax of Rs.354.61 Lakhs for the corresponding quarter of the previous year.
 - 6.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
 - 7.The results for the quarter ended 31st December 2024 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.
 - 8.Figures for the previous periods /year have been regrouped/reclassified wherever necessary.
 - 9.During the previous years, the Company made a payment of ₹41.93 lakhs. However, it has come to light that no interest has been accrued on this amount during the current quarter. This situation is not fully aligned with the requirements outlined in Section 186 of the Companies Act, 2013. The Company is reviewing this matter to ensure future compliance and alignment with statutory obligations.
 10. The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting.
- Additionally, the Company has yet to implement a bill-to-bill adjustment process, which has posed challenges in preparing a precise aging schedule for its creditors. Addressing these outstanding issues remains a priority, and the Company is committed to achieving full compliance and transparency in its reporting.
11. On April 26, 2023, the Company issued a total of 12,837,200 share warrants on a preferential basis. As of the second quarter, 1,500,000 share warrants remained pending for conversion. These pending warrants, which were required to be converted into equity shares by October 26, 2024, were successfully converted within the stipulated timeframe in October. This conversion into equity shares was completed in compliance with regulatory requirements

Place:Hyderabad
Date:14.02.2025



For and on behalf of the Board of Directors
OXYGENTA PHARMACEUTICAL LIMITED

Sai Sudhakar

SAI SUDI AKAR VANKINENI
Managing Director
DIN :00733001



A.M REDDY & D.R REDDY
Chartered Accountants

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of
OXYGENTA PHARMACEUTICAL LIMITED Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,
The Board of Directors,
Oxygenta Pharmaceutical Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited ("the Company") for the quarter ended December 31, 2024 and year to date results for the period October 1st, 2024 to December 31, 2024 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to

H.O #14/186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 | Phone No: 08554-231666
B.O H.No 3-6-640/1/C, Fourth Floor, Street No 9, Himayat Nagar, Hyderabad 500 029 | Phone No : 040-40077393
Mobile No: 9848032382 Email ID: ckreddy1999@yahoo.com




obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants

Firms Registration No: 009068S



D. Rama Krishna Reddy


Partner

Membership No. 209211

UDIN: 25209211BMJBNT3072

Place: Hyderabad

Date: February 14, 2025



STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.:

Statement on deviation / variation in utilization of funds raised	
Name of listed entity	Oxygenta Pharmaceutical Limited
Mode of Fund Raising	Preferential Issue (Conversion of warrants into Equity)
Dates of Raising Funds	1. on 16-10-2024 and 2. on 18-10-2024
Amount Raised	Rs. 2,25,00,000
Report filed for Quarter ended	December 31, 2024
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	NIL
Comments of the auditors, if any	NIL

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation (Amount in ₹)	Modified allocation , if any	Funds Utilized till December 31, 2024 (Amount in ₹)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
a. To repayment of debt of the Company b. For working capital requirement purposes c. For general corporate purposes	Not Applicable	2,25,00,000	Not Applicable	2,25,00,000	Not Applicable	No Remark

Deviation or variation could mean:

- Deviation in the objects or purposes for which the funds have been raised or
- Deviation in the amount of funds actually utilized as against what was originally disclosed or
- Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For **Oxygenta Pharmaceutical Limited**

Sai Sudhakar

Sai Sudhakar Vankineni
Managing Director
DIN: 00733001



OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S.S ORGANICS LIMITED)
(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.
Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038